ILUMYA (Sun Pharma ANZ Pty Ltd)
Product name
ILUMYA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
227 working days (255)
Active ingredients
tildrakizumab
Registration type
NCE/NBE
Indication
ILUMYA (solution for injection) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.